Literature DB >> 29050108

[Evidence-based guideline on diagnosis and treatment of steroid-sensitive, relapsing/steroid-dependent nephrotic syndrome in children(2016)].

.   

Abstract

Entities:  

Year:  2017        PMID： 29050108     DOI： 10.3760/cma.j.issn.0578-1310.2017.10.003

Source DB:  PubMed          Journal:  Zhonghua Er Ke Za Zhi        ISSN： 0578-1310


× No keyword cloud information.
  6 in total

1.  Expression of adipokines in children with primary nephrotic syndrome and its association with hyperlipidemia.

Authors:  Ru-Xin Zhang; Xuan Zhang; Bi-Li Zhang; Zhu-Feng Liu; Shu-Xiang Lin
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2021-08-15

2.  [Clinical assessment of moderate-dose glucocorticoid in the treatment of recurrence of primary nephrotic syndrome in children: a prospective randomized controlled trial].

Authors:  Juan Tu; Chao-Ying Chen; Hai-Yun Geng; Hua-Rong Li; Hua Xia; Yuan Lin; Tian-Tian Lin; Jin-Shan Sun
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-05-15

3.  Clinical effect of different prednisone regimens in the treatment of children with primary nephrotic syndrome and risk factors for recurrence.

Authors:  Hai-Yun Geng; Chao-Ying Chen; Juan Tu; Hua-Rong Li; Pei-Wei DU; Hua Xia; Xiao-Ning Yu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-08-15

Review 4.  A review of nephrotic syndrome and atopic diseases in children.

Authors:  Yue Zheng; Ling Hou; Xiu-Li Wang; Cheng-Guang Zhao; Yue Du
Journal:  Transl Androl Urol       Date:  2021-01

5.  Urinary Sediment mRNA Level of CREBBP and CYBA in Children With Steroid-Resistant Nephrotic Syndrome.

Authors:  Wei Li; Xinyi Shou; Wenqing Xiang; Lin He; Lin Li; Haidong Fu; Jianhua Mao
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

6.  Establishment of relapse risk model and multivariate logistic regression analysis on risk factors of relapse in children with primary nephrotic syndrome.

Authors:  Qian-Qian Peng; Ping Zeng; Xiao-Hua Jiang; Feng-Jun Guan
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.